Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 5.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Morepen Laboratories was 129.70% per year. The lowest was -173.20% per year. And the median was -2.60% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Morepen Laboratories 3-Year FCF Growth Rate Related Terms
NSE:MOREPENLAB vs ZTS: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Morepen Laboratories (NSE:MOREPENLAB) has a 3-Year FCF Growth Rate of 5.10% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Morepen Laboratories and its competitors. According to the industry distribution chart, Morepen Laboratories ranks #347 out of 657 companies in the Drug Manufacturers industry, placing it in the top 52.8%.
Is Morepen Laboratories' 3-Year FCF Growth Rate too high?
Morepen Laboratories' current 3-Year FCF Growth Rate is 5.10%. The Drug Manufacturers industry median 3-Year FCF Growth Rate is 8.70. Morepen Laboratories' value of 5.10% is 41.4% below this industry median. Based on the distribution chart, Morepen Laboratories ranks #347 out of 657 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' 3-Year FCF Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #347 out of 657 companies for 3-Year FCF Growth Rate. This places Morepen Laboratories in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 8.70. Morepen Laboratories' value of 5.10% is 41.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 8.70, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current 3-Year FCF Growth Rate of 5.10% is 41.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 8.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current 3-Year FCF Growth Rate is 5.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹54.87, compared to a current price of ₹120.90 — trading 120.3% above its estimated fair value. The current 3-Year FCF Growth Rate is 5.10% and 41.4% below the Drug Manufacturers industry median of 8.70. Morepen Laboratories' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current 3-Year FCF Growth Rate is 5.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹120.90 is trading 120.3% above its estimated GF Value™ of ₹54.87.
GuruFocus considers Morepen Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
3-Year FCF Growth Rate: 5.10%
GF Value™: ₹54.87 vs. price of ₹120.90 (120.3% above fair value)
Industry Position: 41.4% below the Drug Manufacturers median (#347 of 657)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
64GF Score
Get the complete analysis for NSE:MOREPENLAB
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
